PMC Issues White Paper to Help FDA Update Outdated Rx/Dx Co-development Concept Paper

The PMC's main recommendation is for the FDA to outline areas where regulatory flexibility and alternative clinical trial models are needed to account for the variety of drug/diagnostic development scenarios that can arise.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.